Late breaking abstracts: Colorectal cancer
LB86 – LB98
- LB86: CAPP2 long term follow up: aspirin protects against hereditary cancer
- LB87: Small intestinal atypical carcinoid tumour with clear cell features: a case report and its differential diagnosis
- LB88: Sensitisation of human colon cancer cell lines to TRAIL induced-apoptosis following inhibition of PI3K or HSP90
- LB89: Peripheral Neuropathy (PN) during and 12 months after Capecitabine and Oxaliplatin chemotherapy (CAPOX) for colorectal cancer
- LB90: CD24 expression enhances cell migration and invasion and confers possible stem cell features in colorectal cancer lines
- LB91: Randomised phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC)
- LB92: Randomised phase 3 study of panitumumab with FOLFOX compared to FOLFOX alone as 1st line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial
- LB93: Choice of randomisation time-point in non-inferiority studies of reduced treatment duration: experience from the SCOT study
- LB94: Lifestyle intervention improves exercise capacity and symptoms of fatigue in bowel cancer survivors: pilot RCT
- LB95: Meat, poultry and fish and risk of colorectal cancer: pooled analysis of data from the UK Dietary Cohort Consortium
- LB96: Life-long vegetarianism and risk of colorectal cancer in India: a case-control study
- LB97: Array comparative genomic hybridisation analysis of colorectal cancer shows prognostically relevant differential patterns of DNA copy number alterations in microsatellite stable and unstable tumours
- LB98: Identification of prognostic biomarkers for colorectal cancer
